Investor Presentaiton
Investor presentation
Full year 2018
Slide 98
NovoEight® volumes continue to grow despite increasing
penetration of long-acting FVIII products
Novo Eight® roll-out continues and the number
of patients has steadily increased
Estimated number
of patients¹
3,000
Number of launch countries
Number of patients
2,500
2,000
1,500
1,000
35
28
25
500
16
8
2014
2015
2016
2017
2018
Novo Eight® has potential to increase volume
share in selected segments and markets
Competitive positioning for Novo Eight®
•
Temperature stability at high room temperature and best-in-
class portability
. Uptake driven by Novo Nordisk's strong customer focus and
company recognition within the haemophilia community
•
Continued volume growth especially in less mature markets
with tender opportunities, despite increasing penetration of
long-acting FVIII products
1 Novo Nordisk estimated accumulated patient number. Patient number in 2018 as of November 2018
FVIII: Coagulation factor VIII
novo nordiskView entire presentation